Literature DB >> 29736660

Response to the Letter "Importance of Tumor Burden in the Survival Analyses of Stage IV Colorectal Cancer Patients".

Naveenraj L Solomon1, Sean Maroney2, Carlos Chavez2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29736660     DOI： 10.1007/s11605-018-3790-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


× No keyword cloud information.
  4 in total

1.  Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer.

Authors:  Zeinab Alawadi; Uma R Phatak; Chung-Yuan Hu; Christina E Bailey; Y Nancy You; Lillian S Kao; Nader N Massarweh; Barry W Feig; Miguel A Rodriguez-Bigas; John M Skibber; George J Chang
Journal:  Cancer       Date:  2016-08-01       Impact factor: 6.860

2.  Benefit of Surgical Resection of the Primary Tumor in Patients Undergoing Chemotherapy for Stage IV Colorectal Cancer with Unresected Metastasis.

Authors:  Sean Maroney; Carlos Chavez de Paz; Mark E Reeves; Carlos Garberoglio; Elizabeth Raskin; Maheswari Senthil; Jukes P Namm; Naveenraj Solomon
Journal:  J Gastrointest Surg       Date:  2017-11-09       Impact factor: 3.452

3.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

4.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.